BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18584190)

  • 21. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of the expression of p53 and bcl-2 in patients with laryngeal carcinoma.
    Klatka J
    Eur Arch Otorhinolaryngol; 2001 Dec; 258(10):537-41. PubMed ID: 11829192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma.
    Gomatos IP; Georgiou A; Giotakis J; Manolopoulos L; Apostolou K; Chatzigianni E; Albanopoulos K; Ferekidou E
    ORL J Otorhinolaryngol Relat Spec; 2007; 69(3):159-66. PubMed ID: 17264532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
    Allal AS; Waelchli L; Bründler MA
    Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Survival of patients with laryngeal cancer and some prognostic factors].
    Gryczyński M; Kobos J; Murlewska A; Pietruszewska W
    Otolaryngol Pol; 2003; 57(3):329-40. PubMed ID: 14524174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.
    Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Moul JW
    J Urol; 1996 Oct; 156(4):1511-6. PubMed ID: 8808919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
    Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
    Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis in rectal cancer: prognostic significance in comparison with clinical histopathologic, and immunohistochemical variables.
    Schwandner O; Schiedeck TH; Bruch HP; Duchrow M; Windhoevel U; Broll R
    Dis Colon Rectum; 2000 Sep; 43(9):1227-36. PubMed ID: 11005488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
    Borre M; Stausbol-Gron B; Overgaard J
    J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
    Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
    J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 expression in Tunisian gastric adenocarcinomas.
    Ayed DB; Khabir A; Abid M; Bayrouti MI; Gargouri A; Sellami-Boudawara T; Mokdad-Gargouri R
    Acta Histochem; 2014 Oct; 116(8):1244-50. PubMed ID: 25095748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of Bcl-2 and p53 expression in advanced laryngeal squamous cell carcinoma.
    Friedman M; Lim JW; Manders E; Schaffner AD; Kirshenbaum GL; Tanyeri HM; Caldarelli DD; Coon JS
    Head Neck; 2001 Apr; 23(4):280-5. PubMed ID: 11400228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An evaluation of the prognostic significance of HLA-DR expression in axillary-node-negative breast cancer.
    Sheen-Chen SM; Chou FF; Eng HL; Chen WJ
    Surgery; 1994 Sep; 116(3):510-5. PubMed ID: 8079182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein expression of bax, bcl-2, and p53 in patients with non-Hodgkin's gastric lymphoma: prognostic significance.
    Charalambous GK; Gomatos IP; Konstadoulakis MM; Messaris EG; Manouras AJ; Apostolou AE; Leandros EA; Karayannis MK; Androulakis GA
    World J Surg; 2000 May; 24(5):608-14. PubMed ID: 10787085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.